Pulse Biosciences (NASDAQ:PLSE) Raised to Sell at StockNews.com

Pulse Biosciences (NASDAQ:PLSE) was upgraded by equities research analysts at StockNews.com to a “sell” rating in a research report issued on Tuesday.

Pulse Biosciences Stock Performance

Shares of PLSE stock opened at $18.33 on Tuesday. Pulse Biosciences has a 52 week low of $6.59 and a 52 week high of $22.69. The company’s 50 day moving average price is $17.97 and its two-hundred day moving average price is $16.70.

Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings data on Wednesday, October 30th. The company reported ($0.21) EPS for the quarter. During the same quarter last year, the company earned ($0.19) EPS.

Insider Activity

In other Pulse Biosciences news, Director Robert W. Duggan acquired 56,054 shares of Pulse Biosciences stock in a transaction dated Wednesday, December 11th. The stock was bought at an average cost of $17.35 per share, for a total transaction of $972,536.90. Following the purchase, the director now directly owns 42,228,057 shares in the company, valued at approximately $732,656,788.95. This represents a 0.13 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Burke Thomas Barrett sold 50,000 shares of Pulse Biosciences stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $17.42, for a total value of $871,000.00. Following the completion of the sale, the chief executive officer now directly owns 63,172 shares in the company, valued at approximately $1,100,456.24. This represents a 44.18 % decrease in their position. The disclosure for this sale can be found here. 71.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Pulse Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Quest Partners LLC acquired a new position in Pulse Biosciences during the second quarter worth $91,000. Creative Planning grew its position in shares of Pulse Biosciences by 113.9% in the 3rd quarter. Creative Planning now owns 21,910 shares of the company’s stock valued at $384,000 after acquiring an additional 11,667 shares during the period. Franklin Resources Inc. acquired a new position in shares of Pulse Biosciences during the 3rd quarter worth about $378,000. Rhumbline Advisers raised its holdings in shares of Pulse Biosciences by 6.7% in the 2nd quarter. Rhumbline Advisers now owns 25,729 shares of the company’s stock valued at $288,000 after purchasing an additional 1,608 shares during the period. Finally, Barclays PLC lifted its stake in Pulse Biosciences by 361.4% in the 3rd quarter. Barclays PLC now owns 30,306 shares of the company’s stock valued at $530,000 after purchasing an additional 23,738 shares during the last quarter. Institutional investors own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.